Evidence map›Paper›PMID 41851087›Full record

Trial reportNature communications2026

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.

Valerie Lee, Apoorvaa S Sachidanand, Christina Rodriguez, Junke Wang, Beth Onners, Hanfei Qi, Rose Parkinson, Thomas McPhaul, Jennifer Durham, Ding Ding and 21 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02648282 (A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02648282 phase2completednot on this map

A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2016 to 2022Enrolled58ConditionsPancreatic CancerArmsCyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Valerie LeeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vlee32@jhmi.edu.
Apoorvaa S SachidanandDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0001-6315-992X
Christina RodriguezDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Junke WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Beth OnnersDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hanfei QiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0072-5752
Rose ParkinsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thomas McPhaulDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jennifer DurhamDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ding DingDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amy Hacker-PrietzDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amol K NarangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dung T LeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-2110-7697
Ana De JesusDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael PishvaianDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1165-9041
Eric ChristensonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth D ThompsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8464-9904
Robert A AndersThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arsen OsipovDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew WeissDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William BurnsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard BurkhartDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kelly LafaroDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jin HeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth SugarDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joseph M HermanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth M JaffeeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3841-6549
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6489-6940
Daniel A LaheruDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6646-0200
Lei ZhengDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. zhengl@uthscsa.edu.ORCID http://orcid.org/0000-0003-4163-2541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this Phase II study (NCT02648282) of locally advanced pancreatic cancer (LAPC), 58 patients were enrolled and intended for an immunotherapy including GM-CSF-secreting allogeneic pancreatic cancer vaccine (GVAX) and pembrolizumab and stereotactic body radiation therapy (SBRT) following standard chemotherapy. Fifty-four evaluable patients received two cycles of immunotherapy and SBRT and reassessed for resectability. After resection or biopsy, patients received continued immunotherapy for two years. At a median follow-up of 19.6 months, the median distant metastasis free survival (DMFS), the primary endpoint, for all evaluable patients was 9.8 months. Secondary endpoint analysis shows that, of these, 35 patients (64.8%) were deemed potentially resectable, and 24 underwent R0/R1 resections. Resected patients had a majority of R0 resections (91.7%). The overall resection rate was 44.4%. Patients who underwent resection had a median DMFS of 20.3 months. Median overall survival (OS), a secondary endpoint, for all evaluable patients from the start of the immunotherapy was 21.8 months, with resected patients reaching 29.7 months and unresected patients at 12.1 months. From diagnosis, median OS was 28.2 months, with resected patients achieving 36.7 months, while unresected patients had 19.7 months. In conclusion, the combination of GVAX, pembrolizumab, and SBRT showed promising efficacy in LAPC patients with favorable survival outcomes, especially those who underwent R0/R1 resections. However, patients with unresectable disease still maintained significantly worse DMFS and OS. The regimen demonstrated a manageable safety profile.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCancer VaccinesPancreatic NeoplasmsRadiosurgeryAdultAgedAged, 80 and overCombined Modality TherapyFemaleHumansImmunotherapyMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCancer Vaccinespembrolizumab

Identifiers

PMID41851087
PMCPMC13149998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.